After doing deals with big pharma – Eli Lilly and Co., Merck & Co. Inc., Abbvie Inc. and Bayer AG – Atomwise Inc. announced three partnerships last week with smaller preclinical companies to use its artificial intelligence (AI) platform to develop drugs for their targets.